Claims for Patent: 6,852,834

Summary for Patent: 6,852,834

Title:	Fusion peptides isolatable by phase transition
Abstract:	Genetically-encodable, environmentally-responsive fusion proteins comprising ELP peptides. Such fusion proteins exhibit unique physico-chemical and functional properties that can be modulated as a function of solution environment. The invention also provides methods for purifying the FPs, which take advantage of these unique properties, including high-throughput purification methods that produce high yields (e.g., milligram levels) of purified proteins, thereby yielding sufficient purified product for multiple assays and analyses. The high throughput purification technique is simpler and less expensive than current commercial high throughput purification methods, since it requires only one transfer of purification intermediates to a new multiwell plate.
Inventor(s):	Chilkoti; Ashutosh (Durham, NC)
Assignee:
Application Number:	09/812,382
Patent Claims:	1. A fusion protein comprising: (a) one or more biological molecules selected from the group consisting of peptides and proteins; (b) one or more phase transition proteins that exhibit an inverse phase transition wherein the one or more phase transition proteins are joined to the biological molecule(s) of (a); and (c) optionally, a spacer sequence separating any of the phase transition protein(s) of (b) from any of the biological molecule(s) of (a), wherein the fusion protein retains the inverse phase transition behavior of the phase transition protein(s) of (b) and wherein said phase transition protein(s) has a molecular weight of at least 9,000 Daltons, and wherein the one or more phase transition protein(s) of (b) comprises oligomeric repeats of the pentapeptide Val-Pro-Gly-X-Gly, wherein X is any natural or non-natural amino acid residue, and wherein X optionally varies among oligomeric repeats. 2. The fusion protein of claim 1 wherein the biological molecule of 1(a) comprises a peptide. 3. The fusion protein of claim 1 wherein the biological molecule of 1(a) comprises a biologically active protein. 4. The fusion protein of claim 1 wherein the biological molecule of 1(a) comprises a therapeutic protein. 5. The fusion protein of claim 1 wherein the biological molecule of 1(a) comprises an enzyme useful in industrial biocatalysis. 6. The fusion protein of claim 1 wherein the biological molecule of 1(a) comprises an antibody or antibody fragment. 7. The fusion protein of claim 6 wherein the antibody or antibody fragment has complex forming affinity for an antigenic protein of interest, and wherein upon binding to the antigenic protein of interest, the fusion protein retains its phase transition character. 8. The fusion protein of claim 1 wherein the phase transition is mediated by one or more means selected from the group comprising: changing temperature; changing pH; addition of solutes and/or solvents, side-chain ionization or chemical modification; and changing pressure. 9. The fusion protein of claim 1 wherein the phase transition is mediated by means comprising raising temperature. 10. The fusion protein of claim 1 wherein the X component(s) of the oligomeric repeats comprise(s) a naturally-occurring amino acid residue. 11. The fusion protein of claim 1 wherein the X component(s) of the oligomeric repeats comprise(s) a non-naturally-occurring amino acid residue. 12. The fusion protein of claim 1 wherein X varies among said oligomeric repeats. 13. The fusion protein of claim 1 wherein any two or more of the oligomeric repeats are separated by one or more amino acid residues which do not eliminate the phase transition characteristic of the fusion protein. 14. The fusion protein of claim 1 wherein the ratio of Val-Pro-Gly-X-Gly oligomeric repeats to other amino acid residues of the phase transition protein(s) of 1(b) is greater than about 75%. 15. The fusion protein of claim 1 wherein the ratio of Val-Pro-Gly-X-Gly oligomeric repeats to other amino acid residue of the phase transition protein(s) of 1(b) is greater than about 85%. 16. The fusion protein of claim 1 wherein the ratio of Val-Pro-Gly-X-Gly oligomeric repeats to other amino acid residues of the phase transition protein(s) of 1(b) is greater than about 95%. 17. The fusion protein of claim 1 wherein the spacer sequence comprises a proteolytic cleavage site. 18. The fusion protein of claim 1 wherein the fusion protein further comprises a signal peptide. 19. The fusion protein of claim 18 wherein the signal peptide is cleavable from the fusion protein by enzymatic cleavage. 20. The fusion protein of claim 18 wherein the signal peptide directs secretion of the fusion protein from the cell. 21. The fusion protein of claim 1 wherein the fusion protein is recombinantly produced. 22. The fusion protein of claim 1 wherein any of the biological molecule(s) of 1(a), phase transition protein(s) of 1(b), or spacer sequence of 1(c) (when present) is recombinantly produced. 23. A fusion protein comprising: (a) one or more biological molecules selected from the group consisting of peptides and proteins; (b) one or more phase transition protein(s) that exhibit an inverse phase transition, wherein the one or more phase transition protein(s) are joined to the biological molecule(s) of (a); and (c) optionally, a spacer sequence separating any of the phase transition protein(s) of (b) from any of the biological molecules of (a), wherein the fusion protein retains the inverse phase transition behavior of the phase transition proteins of (b) and wherein said phase transition protein(s) comprises at least thirty repeats of the pentapeptide Val-Pro-Gly-X-Gly, in which X is any natural or non-natural amino acid residue. 24. The fusion protein of claim 23 wherein the phase transition is mediated by means comprising raising temperature. 25. A fusion protein comprising: (a) one or more biological molecules selected from the group consisting of peptides and proteins; (b) one or more phase transition proteins that exhibit an inverse phase transition, wherein the one or more phase transition proteins are joined to the biological molecule(s) of (a); and (c) optionally, a spacer sequence separating any of the phase transition protein(s) of (b) from any of the biological molecule(s) of (a), wherein the fusion protein retains the inverse phase transition behavior of the phase transition proteins of (b), wherein said phase transition protein(s) comprises oligomeric repeats of the pentapeptide Val-Pro-Gly-X-Gly, in which X is any natural or non-natural amino acid residue, and wherein said phase transition protein(s) has a molecular weight of at least 9,000 Daltons, wherein the one or more biological molecules of (a) is proteolytically cleavable from the fusion protein; and wherein the phase transition is mediated by one or more means selected from the group comprising: changing temperature; changing pH; addition of solutes and/or solvents, side-chain ionization or chemical modification; and changing pressure. 26. The fusion protein of claim 25 wherein the phase transition is mediated by raising temperature. 27. The fusion protein of claim 8, wherein the phase transition is mediated by addition of solute. 28. The fusion protein of claim 27, wherein the solute comprises an organic solute. 29. The fusion protein of claim 27, wherein the solute comprises an ionic solute. 30. The fusion protein of claim 29, wherein the ionic solute comprises a salt. 31. The fusion protein of claim 30, wherein the salt comprises NaCl. 32. An elastin-like polypeptide (ELP) fusion protein comprising a protein of interest and an elastin-like polypeptide component coupled by a cleavage site in a composition comprising a solvent medium in which the ELP fusion protein exhibits an inverse phase transition wherein the phase transition is mediated by at least one change selected from the group consisting of: (a) changing temperature; (b) changing pH; (c) addition of solutes and/or solvents; (d) side-chain ionization or chemical modification; and (e) changing pressure, wherein the elastin-like polypeptide component comprises oligomeric repeats of the pentapeptide Val-Pro-Gly-X-Gly, in which X is any natural or non-natural amino acid residue, and wherein said phase transition protein(s) has a molecular weight of at least 9,000 Daltons. 33. The ELP fusion protein of claim 32, wherein the protein of interest is cleavable from the elastin-like polypeptide component at the cleavage site to yield the protein of interest and the elastin-like polypeptide component as cleavage products. 34. The fusion protein of claim 1, wherein said one or more biological molecules of (a) is cleavable from the fusion protein by a cleavage agent. 35. The ELP fusion protein of claim 33, wherein said cleavage agent is a proteolytic agent for proteolytically cleaving the cleavage site of the fusion protein. 36. The fusion protein of claim 1 wherein the phase transition protein(s) comprise a .beta.-turn structure. 37. The fusion protein of claim 23, having a phase transition temperature in a range of from about 35 to about 60.degree. C. 38. The fusion protein of claim 1 wherein the phase transition protein(s) of (b) are joined to the N-terminus of the biological molecule(s) of (a). 39. The fusion protein of claim 17 wherein the proteolytic cleavage site is cleavable by a protease agent selected from the group consisting of serine, cysteine, aspartyl and metallo-proteases. 40. A fusion protein comprising: (a) one or more biological molecules selected from the group consisting of peptides, therapeutic proteins and antibodies or antibody fragments; (b) one or more phase transition proteins that exhibit an inverse phase transition, wherein the one or more phase transition proteins are joined to the biological molecule(s) of (a); and (c) optionally, a spacer sequence separating any of the phase transition protein(s) of (b) from any of the biological molecule(s) of (a), wherein the one or more phase transition proteins of (b) comprises at least thirty repeats of the pentapeptide Val-Pro-Gly-X-Gly, in which X is any natural or non-natural amino acid residue, wherein the phase transition is mediated by one or more means selected from the group comprising: changing temperature; changing pH; addition of solutes and/or solvents, side-chain ionization or chemical modification; and changing pressure, wherein the fusion protein retains the inverse phase transition behavior of the one or more phase transition proteins of (b). 41. A fusion protein comprising: (a) one or more biological molecules selected from the group consisting of superoxide dismutase, interferon, asparaginease, glutamase, arginase, arginine deaminase, adenosine deaminase ribonuclease, trypsin, chromotrypsin, papin, insulin, calcitonin, adrenocorticotropic hormone (ACTH), glucagon. somatosin, somatropin, somatomedin, parathyroid hormone, erthyropoietin, hypothalamic releasing factors, prolactin, thyroid stimulating hormones, endorphins, enkephalins, and vasopressin; (b) one or more phase transition proteins that exhibit an inverse phase transition, wherein the one or more phase transition proteins are joined to the biological molecule(s) of (a), and wherein said phase transition protein(s) comprises oligomeric repeats of the pentapeptide Val-Pro-Gly-X-Gly, in which X is any natural or non-natural amino acid residue; and (c) optionally, a spacer sequence separating any of the phase transition protein(s) of (b) from any of the biological molecule(s) of (a), wherein the fusion protein retains the inverse phase transition behavior of the phase transition proteins of (b).

Details for Patent 6,852,834

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	HUMATROPE	somatropin	For Injection	019640	06/23/1987		2020-03-20
Eli Lilly And Company	HUMATROPE	somatropin	For Injection	019640	10/16/1986		2020-03-20
Eli Lilly And Company	HUMATROPE	somatropin	For Injection	019640	02/04/1999		2020-03-20
Emd Serono, Inc.	SAIZEN	somatropin	For Injection	019764	10/08/1996		2020-03-20
Emd Serono, Inc.	SAIZEN	somatropin	For Injection	019764	08/29/2000		2020-03-20
Emd Serono, Inc.	SAIZEN	somatropin	For Injection	019764	01/16/2007		2020-03-20
Ferring Pharmaceuticals Inc.	ZOMACTON	somatropin	For Injection	019774	05/25/1995		2020-03-20